SAN DIEGO, March 7, 2018 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences,
will present at the following investor conferences:
- Cowen and Company 38th Annual Health Care Conference
at 10:00 a.m. ET on Wednesday, March
14, 2018, in Boston.
- Barclays Global Healthcare Conference at 1:35 p.m. ET on
Thursday, March 15, 2018, in
Miami.
- Oppenheimer 28th Annual Healthcare Conference at
10:55 a.m. ET on Wednesday, March 21,
2018, in New York City.
The live presentations will be webcast and may be accessed on
the Company's website under Investors at http://www.neurocrine.com.
A replay of the presentation will be available on the website
approximately one hour after the conclusion of the event and will
be archived for one month.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a San Diego based
biotechnology company focused on neurologic, psychiatric and
endocrine related disorders. The Company markets
INGREZZA® (valbenazine) capsules in the United
States for the treatment of adults with tardive
dyskinesia. INGREZZA is a novel, selective vesicular monoamine
transporter 2 (VMAT2) inhibitor, and is the first FDA approved
product indicated for the treatment of adults with tardive
dyskinesia. The Company's three late-stage clinical programs
are: elagolix, a gonadotropin-releasing hormone antagonist for
women's health that is partnered with AbbVie Inc.; opicapone,
a novel, once-daily, peripherally-acting, highly-selective
catechol-o-methyltransferase inhibitor under investigation as
adjunct therapy to levodopa in Parkinson's patients; and INGREZZA,
a novel, once-daily, selective VMAT2 inhibitor under investigation
for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-300607675.html
SOURCE Neurocrine Biosciences, Inc.